Sharps Technology Inc

Sharps Technology Inc(STSS)股票分析

$1.840

+0.020 (+1.10%)收盤時

Loading chart…
High
1.980
Open
1.980
VWAP
1.88
Vol
520.56K
Mkt Cap
4.76M
Low
1.810
Amount
976.92K
EV/EBITDA, TTM
0.00

SkyAI, Inc., formerly Sharps Technology, Inc., is a medical device and pharmaceutical packaging company. The Company is engaged in offering patented smart-safety syringe products to the healthcare industry. The Company's smart safety syringe products, such as Securgard, Sologard, and Sharps Provensa, are ultra-low waste syringes that incorporate both passive and active safety and reuse prevention features. It Sharps Securegard and Sologard safety syringe product lines incorporate both active and passive safety features and have been designed to address the primary administration concerns with syringe delivery systems, including accidental needlestick injuries, wasted medicine/dead space and reuse prevention. It also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. It has a manufacturing facility in Hungary and is pursuing plans to expand its manufacturing capacity in the United States.

AI analysis of Sharps Technology Inc (STSS)

sell

Sharps Technology Inc (STSS), now rebranding to SkyAI, is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The current setup is weak technically, insider selling is rising sharply, and there is no strong proprietary buy signal. Even with the pre-market price at 1.84, the stock is below the pivot and under bearish moving averages, so I would not buy it now. My direct view: sell/avoid for now, not a buy.

估值指標

The current forward P/E ratio for Sharps Technology Inc (STSS) is 0.00, compared to its 5-year average forward P/E of -1.60.

Forward P/E

Fair
5Y Average P/E
-1.60
Current P/E
0.00
高估
0.38
低估
-3.58

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
3.01
Current EV/EBITDA
0.00
高估
10.74
低估
-4.72

Forward P/S

Fair
5Y Average P/S
8.45
Current P/S
0.00
高估
35.73
低估
-18.83

事件時間軸

2026-05-27 (ET)

07:30:00

Sharps Technology Rebrands to SkyAI and Changes Ticker Symbol

2026-05-14 (ET)

18:30:00

Sharps Technology Adopts Stockholder Rights Plan to Protect Interests

2026-02-27 (ET)

11:01:00

Circle Raises Price Target to $160, USDC Circulation Grows 72%

2026-02-25 (ET)

09:10:00

Sharps Technology Partners with The Tie to Strengthen Solana's Institutional Infrastructure

2026-02-06 (ET)

10:40:00

Strategy Reports Q4 Loss of $3.03 per Share, Price Target Cut to $250

資訊

STSS FAQ — answered by Alphio AI

SkyAI, Inc., formerly Sharps Technology, Inc., is a medical device and pharmaceutical packaging company. The Company is engaged in offering patented smart-safety syringe products to the healthcare industry. The Company's smart safety syringe products, such as Securgard, Sologard, and Sharps Provensa, are ultra-low waste syringes that incorporate both passive and active safety and reuse prevention features. It Sharps Securegard and Sologard safety syringe product lines incorporate both active and passive safety features and have been designed to address the primary administration concerns with syringe delivery systems, including accidental needlestick injuries, wasted medicine/dead space and reuse prevention. It also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. It has a manufacturing facility in Hungary and is pursuing plans to expand its manufacturing capacity in the United States. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Sharps Technology Inc (STSS), now rebranding to SkyAI, is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The current setup is weak technically, insider selling is rising sharply, and there is no strong proprietary buy signal. Even with the pre-market price at 1.84, the stock is below the pivot and under bearish moving averages, so I would not buy it now. My direct view: sell/avoid for now, not a buy.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始